Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model

AN12855 is a direct, cofactor-independent inhibitor of InhA in Mycobacterium tuberculosis. In the C3HeB/FeJ mouse model with caseous necrotic lung lesions, AN12855 proved efficacious with a significantly lower resistance frequency than isoniazid. AN12855 drug levels were better retained in necrotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, Gregory T., Ektnitphong, Victoria A., Scherman, Michael S., McNeil, Matthew B., Dennison, Devon, Korkegian, Aaron, Smith, Anthony J., Halladay, Jason, Carter, David S., Xia, Yi, Zhou, Yasheen, Choi, Wai, Berry, Pamela W., Mao, Weimin, Hernandez, Vincent, Alley, M. R. K., Parish, Tanya, Lenaerts, Anne J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496157/
https://www.ncbi.nlm.nih.gov/pubmed/30745397
http://dx.doi.org/10.1128/AAC.02071-18
Descripción
Sumario:AN12855 is a direct, cofactor-independent inhibitor of InhA in Mycobacterium tuberculosis. In the C3HeB/FeJ mouse model with caseous necrotic lung lesions, AN12855 proved efficacious with a significantly lower resistance frequency than isoniazid. AN12855 drug levels were better retained in necrotic lesions and caseum where the majority of hard to treat, extracellular bacilli reside. Owing to these combined attributes, AN12855 represents a promising alternative to the frontline antituberculosis agent isoniazid.

Ejemplares similares